The International Myeloma Foundation Says Previously Untreated Patients Could Benefit from FDA Approval of VELCADE® for ‘Front-Line’ Use

NORTH HOLLYWOOD, Calif.--(BUSINESS WIRE)--The International Myeloma Foundation (IMF) – supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians – today applauded the decision by the US Food and Drug Administration (FDA) to expand the benefits of VELCADE® (bortezomib) for injection to a wider range of multiple myeloma patients. Since 2003, VELCADE has been approved for relapsed patients who have had at least one prior therapy. The FDA has now granted the use of VELCADE to previously untreated patients with multiple myeloma.